Kolon’s TG-C Misses Phase 3 Endpoints
Kolon TissueGene’s allogeneic cell and gene therapy TG-C failed both co-primary endpoints in ACTiVION-II, a 531-patient U.S. Phase 3 study in knee osteoarthritis. Pain and WOMAC function improved substantially in both groups, but TG-C…
